Under a clinical light in a paper gown, I heard the phrase that reframed months of discomfort: vaginal atrophy. For a long time I dismissed recurrent pain with quick fixes—lots of water, ridiculous quantities of lube, and the hope a hearty flush would make urinary and sexual pain go away. The exam made the issue real: tissue that was irritated, fragile, and reactive to touch. I cracked a nervous joke about scrubbing too hard before appointments; my gynecologist did not laugh. That moment crystallized a private problem into a medical diagnosis, and it arrived while I was already negotiating the effects of testosterone and the social reshaping that comes with a gender transition.
Processing the diagnosis sent me to therapy and to community conversations. I realized my sexual history was braided with my gender evolution: years of performing a top role to fit into a stud identity, followed by a later, hard-won freedom to explore being a receptive partner. The loss of that option after discovering vaginal atrophy felt like a double surrender—of a sexual practice I had finally learned to enjoy and of the bodily autonomy I had gained through transition. That grief was not just about sex; it was about how social norms, internalized stigma, and medical gaps shape which pleasures feel allowed or possible.
How diagnosis intersected with gender and desire
The diagnosis reframed more than anatomy: it revealed how sexual roles can be conditioned by gender expectations. For years I avoided receiving pleasure that could be read as too feminine or “too gay,” and I topped as a kind of social armor. After college, becoming more open about being nonbinary and trans unlocked a spectrum of sexual experiences across partners, positions, and genitals that taught me what I actually wanted. Learning to bottom was part of that self-discovery, so losing access to receptive sex because of vaginal atrophy felt like a setback in a personal project of authenticity. At the same time, the treatment I chose—low-dose estrogen for local symptom relief—reminded me that managing hormones is often an ongoing negotiation between gender goals and sexual health outcomes.
Medical landscape and research gaps
One of the most frustrating elements of this experience is how little mainstream research addresses the realities of people assigned female at birth (AFAB) who take testosterone. Most clinical literature about thinning and drying of vaginal tissue focuses on cisgender women in menopause or breast cancer care, leaving trans men, transmasculine folks, many nonbinary people, and some intersex individuals largely invisible. That invisibility means many start HRT without a clear conversation about sexual side effects, and clinicians often rely on generalized guidance that does not reflect trans bodies. Access to an LGBTQ+-competent gynecologist made a difference for me, but that access is not guaranteed, especially in places where trans healthcare faces political and funding threats.
Who is affected
People impacted by this condition include trans men, transmasculine individuals, nonbinary people, and some intersex people who are AFAB and use testosterone. The constellation of effects—tissue thinning, increased fragility, dryness, and discomfort during penetration or sexual activity—shows up across this population but is rarely centered in research or clinical guidelines. When clinicians overlook these experiences, patients may get inadequate advice, turn to peer networks for solutions, or accept reduced sexual satisfaction as an inevitable trade-off of transition. These outcomes point to a broader failure to integrate trans bodies into gynecological care and sexual health studies.
Treatment, coping and advocacy
In my case, a low dose of localized estrogen produced measurable relief, which affirmed that some interventions can restore comfort and expand sexual options. But a clinical success for one person does not erase the systemic problem: no one should feel forced to choose between their gender affirmation and their sexual fulfillment. Coping strategies used by community members range from changes in lubrication and sexual practices to medical treatments and counseling. Still, the real fix requires better informed consent conversations before starting HRT, more clinician training in trans and nonbinary reproductive health, and research that includes diverse AFAB experiences so treatments and risk counseling are accurate and equitable.
What needs to change
Improving outcomes means expanding research priorities, improving medical education, and protecting access to competent care. Studies must include trans and nonbinary cohorts so that conditions like vaginal atrophy get recognized beyond menopausal contexts. Providers need practical guidance on screening, prevention, and treatment that is sensitive to gender goals and sexual desires, while insurers should cover both local therapies and supports such as gynecological visits tailored to trans patients. Ultimately, ensuring sexual freedom for people on HRT is a matter of health equity: everyone deserves accurate information, respectful clinical spaces, and options that honor their bodily autonomy and pleasure.